Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity

Boris Engels, Victor H. Engelhard, John Sidney, Alessandro Sette, David C. Binder, Rebecca B. Liu, David M Kranz, Stephen C. Meredith, Donald A. Rowley, Hans Schreiber

Research output: Contribution to journalArticle

Abstract

Cancers often relapse after adoptive therapy, even though specific T cells kill cells from the same cancer efficiently in vitro. We found that tumor eradication by T cells required high affinities of the targeted peptides for major histocompatibility complex (MHC) class I. Affinities of at least 10 nM were required for relapse-free regression. Only high-affinity peptide-MHC interactions led to efficient cross-presentation of antigen, thereby stimulating cognate T cells to secrete cytokines. These findings highlight the importance of targeting peptides with high affinity for MHC class I when designing T cell-based immunotherapy.

Original languageEnglish (US)
Pages (from-to)516-526
Number of pages11
JournalCancer Cell
Volume23
Issue number4
DOIs
StatePublished - Apr 15 2013

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Cite this

Engels, B., Engelhard, V. H., Sidney, J., Sette, A., Binder, D. C., Liu, R. B., Kranz, D. M., Meredith, S. C., Rowley, D. A., & Schreiber, H. (2013). Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell, 23(4), 516-526. https://doi.org/10.1016/j.ccr.2013.03.018